SCHEMBL24978636

SCHEMBL24978636

CC(=O)NC(CCC(N)=O)C(=O)OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.56
ALDH1A1 P00352 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MME P08473 1/20 0.47
ECE1 P42892 1/20 0.47
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA3 P07451 1/20 0.45
CA4 P22748 1/20 0.45
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
CA7 P43166 1/20 0.45
CACNA1C Q13936 1/20 0.45
SCN9A Q15858 1/20 0.45
CA9 Q16790 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7046063 1.00 TACR1 (0.56) TACR1ALDH1A1KMT2AMEN1HPGD
SCHEMBL30665417 0.89 TACR1 (0.59) TACR1ALDH1A1KMT2AMEN1HPGD
SCHEMBL4919342 0.88 MME (0.56) TACR1SMN1; SMN2MMEECE1CTSK
SCHEMBL28711261 0.88 ALDH1A1 (0.66) TACR1ALDH1A1KMT2AMEN1HPGD
SCHEMBL28711262 0.88 ALDH1A1 (0.66) TACR1ALDH1A1KMT2AMEN1HPGD
SCHEMBL29682481 0.88 MME (0.56) TACR1SMN1; SMN2MMEECE1CTSK
SCHEMBL4919347 0.88 MME (0.56) TACR1SMN1; SMN2MMEECE1CTSK
SCHEMBL28993693 0.88 MME (0.56) TACR1SMN1; SMN2MMEECE1CTSK
SCHEMBL7047407 0.87 CA12 (0.46) TACR1ALDH1A1KMT2AMEN1HPGD
SCHEMBL23422204 0.85 TACR1 (0.55) TACR1ALDH1A1KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025037775-A1 COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DIABETES AND RELATED DISEASES 주식회사 마이크로엑스 2025-02-20 WO disclosed
WO-2024147532-A1 COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF SEPSIS 주식회사 마이크로엑스 2024-07-11 WO disclosed
WO-2023219227-A1 COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING ALZHEIMER'S DISEASE 주식회사 마이크로엑스 2023-11-16 WO disclosed
US-20230026277-A1 COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE MICROX CO., LTD. (KR) 2023-01-26 US disclosed
CN-114760995-A Composition for preventing, alleviating or treating respiratory diseases 微艾克斯有限公司 2022-07-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026277-A1 COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF RESPIRATORY DISEASE RELA, CSNK2A1, CSNK1G1 TACR1 4031/4885ALDH1A1 4284/4885KMT2A 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.